Mandate

Vinge advises Irisity in conjunction with the acquisition of Agent Vi and a directed share issue

Vinge has advised Irisity AB (publ) in connection with its acquisition of all shares in the Israeli company Agent Video Intelligence Ltd for a purchase price of approximately SEK 580 million.

The purchase price shall be paid in cash, and in part by way of newly issued shares in Irisity. Closing is subject to a resolution adopted at Irisity’s extraordinary general meeting to authorise the board of directors to adopt a resolution concerning a non-cash issue.

In connection with the closing of the transaction, Vinge advised Irisity regarding a directed share issue that was performed as an accelerated bookbuilding arranged by Erik Penser Bank at a subscription price of SEK 49. Irisity received SEK 130 million before issue costs.

Vinge’s team consisted of Anders StridAnna Ståhlklo (M&A), Edin Agic (ECM) and Adrian Filipovic (ECM). S. Horowitx&Co acted as legal counsel in Israel in connection with the acquisition.

Related

Vinge advises Atria Sverige in conjunction with an investment in Cookin Food

Atria Sverige has acquired a 25 per cent stake in the Swedish convenience food company Cookin Food Sweden AB. The transaction has been performed through the acquisition of shares in Bite Delight AB, which owns Cookin Food Sweden AB. Atria holds an option to acquire the remaining shares in Bite Delight AB after 2028.
March 04, 2026

Vinge advises Revivo Group on the acquisition of Solidenergy

Revivo Group, a portfolio company of Helix Kapital, has acquired Solidenergy, a leading provider of surface treatment services in the Norwegian market. The company operates within the energy, offshore and infrastructure sectors and is headquartered in Ågotnes outside Bergen. Solidenergy employs approximately 600 people.
March 03, 2026

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a partially guaranteed rights issue which is expected to provide Oncopeptides with proceeds of approximately SEK 200 million before deduction of transaction costs.
March 03, 2026